Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

OPKO IP Holdings II, Inc.216 enrolled

Overview

This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of CTAP101 Capsules administered for 26 weeks to treat SHPT in subjects ≥18 years of age with stage 3 or 4 CKD and vitamin D insufficiency. The study will be conducted at approximately 40 sites within the United States (US). Approximately 550 subjects will be screened to randomize approximately 210 eligible subjects, stratified by CKD stage (approximately 105 subjects in each stage) in a 2:1 ratio to receive either CTAP101 Capsules or matching placebo. An Interactive Voice Response System (IVRS) will provide study treatment group assignments using the computer-generated randomization code provided by the IVRS vendor. Subjects will receive an initial daily dose of 1 capsule (CTAP101 Capsules, 30 µg, or matching placebo) for the first 12 weeks. After l2 weeks (visit 8) and per pre-defined criteria, the dose may be increased in a blinded fashion by the IVRS with oversight by an independent medical monitor.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

216

Conditions

Chronic Kidney Disease Hyperparathyroidism, Secondary Vitamin D Deficiency

Interventions

CTAP101 30 μg capsulesDRUG

CTAP101 30 μg capsule taken daily at bedtime

Sugar pill to CTAP101 30 μg capsulesOTHER

Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Urinary albumin excretion ≤ 3000 mcg/mg of creatinine 2. Stage 3 or 4 CKD 3. Plasma iPTH: ≥ 85 pg/mL and \< 500 pg/mL 4. Serum Ca: ≥ 8.4 mg/dL and \< 9.8 mg/dL 5. Serum P: ≥ 2.0 mg/dL and \< 5.0 mg/dL 6. Serum 25-hydroxyvitamin D: ≥ 10 ng/mL and \< 30 ng/mL. 7. Stable dose of Vitamin D therapy ≤ 1600 IU/day and receiving same dose for at least 2 months Exclusion Criteria: 1. History of kidney transplant or parathyroidectomy 2. Spot urine calcium:creatinine ratio \> 0.2 (\>200 mg/g Cr) 3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event or hepatitis 4. Currently on dialysis 5. Use of pharmacological dose of ergocalciferol or cholecalciferol (≥ 50,000 IU mcg per month) during the study

Locations (1)

OPKO Renal

Bannockburn, Illinois, United States

Outcomes

Primary Outcomes

Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline

Number of subjects in the intent to treat population attaining mean decrease in plasma intact Parathyroid Hormone (iPTH) of ≥30% from P\\pre-treatment baseline in the efficacy assessment phase (EAP) referred to as responders

Time frame: Approximately 6 months

Secondary Outcomes

Number of Participants in the Per Protocol Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline

Number of subjects in the per protocol population attaining a mean decrease in plasma intact parathyroid hormone (iPTH) of ≥30% from pre-treatment baseline in the efficacy assessment phase (EAP), referred to as responders

Time frame: Approximately 6 months

Subjects in the Intent to Treat Population With Normal Serum Total 25-hydroxyvitamin D

Subjects in the intent to treat population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/dL)

Time frame: Approximately 6 months

Subjects in the Per Protocol Population With Normal Serum Total 25-hydroxyvitamin D

Subjects in the per protocol population with normal serum total 25-hydroxyvitamin D (\>/= 30 ng/mL)

Time frame: Approximately 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.